Rebecca Dent, MD, MSc, of the National Cancer Center in Singapore, gives insights on the use of antibody-drug conjugates (ADCs) in early breast cancer treatment. Rebecca Dent, MD, MSc, deputy CEO and ...
BERLIN -- Antibody-drug conjugates (ADCs) targeting Trop2 made a strong case as first-line standard of care for metastatic triple-negative breast cancer (TNBC) ineligible for immunotherapy, according ...
Triple negative breast cancer (TNBC) is one of the most aggressive and hardest forms of breast cancer to treat, but a new study led by Weill Cornell Medicine suggests a surprising way to stop it from ...
Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers, such as PD-L1 expression or ...
A national cohort study found that the incidence of triple-negative breast cancer (TNBC) is highest among Black women living in the most socioeconomically disadvantaged neighborhoods, and the ...
Immunotherapy has emerged as a key treatment approach for several solid tumors. However, its role in early-stage breast cancer continues to evolve. The immune microenvironment of breast cancer is ...
HONG KONG, Dec. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback